{"entity":{"id":"nct05180799","kind":"trial","name":"A Phase 1/2 Study of BA3071 in Patients With Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of BA3071, Nivolumab, Pembrolizumab in melanoma, run by BioAtla, Inc., active and no longer recruiting.","summary":"A Phase 1/2 Study of BA3071 in Patients With Solid Tumors is a phase 1/2 interventional study registered as NCT05180799 by BioAtla, Inc., with 320 participants planned, started 2022-08-03 and due to reach its primary completion in 2025-03-19. Interventions recorded: BA3071, Nivolumab, Pembrolizumab, Pemetrexed (Alimta). Conditions listed: NSCLC, Melanoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05180799","url":"https://clinicaltrials.gov/study/NCT05180799"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["ba3071","nivolumab","pembrolizumab","pemetrexed"],"companies":["bioatla"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05180799","phase":"1/2","setting":"A Phase 1/2 Study of BA3071 in Patients With Solid Tumors","sponsor":"BioAtla, Inc.","participation":[{"nct":"NCT05180799","source":"https://clinicaltrials.gov/study/NCT05180799","fetchedAt":"2026-10-07T16:53:36.501Z","studySha256":"f5505505eed9a133cf7dd39f392689d8b79b3e96e6ade88c552d822574509fad","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2025-06-15","leadSponsor":"BioAtla, Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":320,"enrolmentType":"ESTIMATED","siteCount":12,"recruitingSiteCount":0,"countries":["Australia","United States"]}],"started":"2022-08-03","startedType":"actual","enrolled":320,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05180799/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"ba3071","kind":"drug","name":"BA3071","route":"/drugs/ba3071/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"}],"company":[{"id":"bioatla","kind":"company","name":"BioAtla","route":"/companies/bioatla/"}]}}